Table 2. Distribution of markers in early and advanced NSCLC versus Controls.
| Marker | Control/ Case | Median | Range | p a | |
|---|---|---|---|---|---|
| HB-EGF (pg/mL) | Control | 196.50 | 32.00–4661.00 | ||
| NSCLC | |||||
| NSCLC I+II | 159.00 | 56.00–435.00 | 0.630 | ||
| NSCLC III+IV | 190.00 | 24.00–1823.00 | 0.698 | ||
| EGF (pg/mL) | Control | 340.82 | 98.01–1160.42 | ||
| NSCLC | |||||
| NSCLC I+II | 792.82 | 388.23–1176.89 | <0.001 | ||
| NSCLC III+IV | 477.74 | 144.23–1158.32 | 0.012 | ||
| sEGFR (ng/mL) | Control | 34.13 | 20.82–49.57 | ||
| NSCLC | |||||
| NSCLC I+II | 38.28 | 29.17–46.44 | 0.375 | ||
| NSCLC III+IV | 37.14 | 21.90–46.28 | 0.375 | ||
| sCD26 (ng/mL) | Control | 473.00 | 122.00–998.00 | ||
| NSCLC | |||||
| NSCLC I+II | 396.00 | 206.00–640.00 | 0.116 | ||
| NSCLC III+IV | 356.00 | 136.00–945.00 | <0.001 | ||
| VEGF (pg/mL) | Control | 542.70 | 39.73–2631.56 | ||
| NSCLC | |||||
| NSCLC I+II | 469.86 | 227.00–1353.08 | 0.990 | ||
| NSCLC III+IV | 663.85 | 81.54–1856.40 | 0.028 | ||
| CAL (ng/mL) | Control | 129.44 | 33.13–421.23 | ||
| NSCLC | |||||
| NSCLC I+II | 196.16 | 120.73–426.99 | 0.002 | ||
| NSCLC III+IV | 247.06 | 107.71–482.89 | <0.001 | ||
a Mann-Whitney U (two-sided test) for comparison among the control group and early and advanced NSCLC stages. P-values were corrected by the Holm method to prevent for inflation of the type I error due to multiple testing (corrections based on multiplicity given by controls subtypes and LC staging).